Impact of clinicopathological features on immune-based combinations for advanced urothelial carcinoma: a meta-analysis.
Future Oncol
; 18(6): 739-748, 2022 Feb.
Article
en En
| MEDLINE
| ID: mdl-35048736
ABSTRACT
Aims:
Immune checkpoint inhibitors (ICIs) have recently revolutionized the treatment landscape of metastatic urothelial carcinoma. The authors performed a meta-analysis aiming to evaluate the predictive value of Eastern Cooperative Oncology Group performance status, age, sex, liver metastasis and histology in trials comparing first-line ICI-based combinations with chemotherapy in metastatic urothelial carcinoma patients.Methods:
Hazard ratios were analyzed.Results:
ICI-based combinations significantly decreased the risk of death in several clinicopathological subgroups, including patients with no liver metastases (hazard ratio 0.84; 95% CI 0.74-0.95) and those with an Eastern Cooperative Oncology Group performance status of 0 (hazard ratio 0.84; 95% CI 0.72-0.97).Conclusion:
The benefit of ICI-based combinations over chemotherapy in metastatic urothelial carcinoma was consistent across several clinicopathological subgroups, although a proportion of patients responded to chemotherapy alone.Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Neoplasias de la Vejiga Urinaria
/
Carcinoma de Células Transicionales
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Inhibidores de Puntos de Control Inmunológico
Tipo de estudio:
Prognostic_studies
/
Systematic_reviews
Límite:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Future Oncol
Año:
2022
Tipo del documento:
Article
País de afiliación:
Italia